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Pulmonary Resection in Patients Aged 80 Years or Over
with Clinical Stage I Non-small Cell Lung Cancer
Prognostic Factors for Overall Survival and Risk Factors for
Postoperative Complications
Jiro Okami, MD,* Masahiko Higashiyama, MD,* Hisao Asamura, MD,† Tomoyuki Goya, MD,‡
Yoshihiko Koshiishi, MD,‡ Yasunori Sohara, MD,§ Kenji Eguchi, MD, Masaki Mori, MD,¶
Yoichi Nakanishi, MD,# Ryosuke Tsuchiya, MD,† and Etsuo Miyaoka, PhD,**
for the Japanese Joint Committee of Lung Cancer Registry
Introduction: This retrospective study was designed to identify the
predictors of long-term survival and the risk factors for complica-
tions after surgery in patients aged 80 years or older with clinical
(c)-stage I non-small cell lung cancer.
Methods: The Japanese Joint Committee of Lung Cancer Registry
collated the clinicopathological profiles and outcomes of 13,344
patients who underwent pulmonary resection for primary lung can-
cer in 1999. The data of 367 patients aged 80 years or older with
c-stage I non-small cell lung cancer were analyzed for prognostic
factors and risk factors for postoperative complications.
Results: The median age was 82 years (range, 80–90 years). Of the
total patient number, 102 (27.8%) had some form of comorbidity
diagnosed preoperatively. Thirty-one (8.4%) patients presented with
postoperative complications, and the operative mortality was 1.4%.
The 5-year survival rates were 55.7% for c-stage I patients, 62.0%
for c-stage IA, and 47.2% for c-stage IB . Advanced pathologic stage
and comorbidity were significant independent predictors of short-
ened survival (p  0.0001 and p  0.032, respectively). Comorbid-
ity and mediastinal lymph node dissection were identified as factors
that increased the risk of postoperative complications (p  0.0001
and p 0.036, respectively). Survival rates were independent of the
extent of pulmonary resection (lobectomy or limited resection).
Conclusions: Octogenarian patients with c-stage I lung cancer in
this study had a satisfactory long-term outcome and low-mortality
rate. Comorbidity is a factor associated with both prognosis and
operative risks. A selection of the patients who would be curable
without mediastinal lymph node dissection after an accurate preop-
erative staging is beneficial to decrease the postoperative complica-
tions because this procedure is a risk factor.
Key Words: Clinical stage I lung cancer, Surgery, Octogenarian,
Prognostic factor, Risk factor for postoperative complication, Lim-
ited resection.
(J Thorac Oncol. 2009;4: 1247–1253)
The average age of the general population is increasing inmany countries including Japan.1 According to the Japa-
nese national statistics on population, the proportion of peo-
ple older than 80 years will swell from 5.2% in 2006 to 9.6%
in 2020.2 Lung cancer is the leading cause of cancer-related
deaths in many countries, and patients older than 80 years
account for 14% of all lung cancers.3,4 Thus, the number of
elderly lung cancer patients is increasing rapidly worldwide.
The current gold standard treatment of early-stage lung
cancer is the resection of the primary tumor plus the lymph
nodes, whether they are involved or not.5 Pulmonary resec-
tion is feasible and safe in octogenarians, given the appropri-
ate selection of surgical candidates,6–10 and evidence-based
guidelines recommend that lung cancer patients should not be
denied resection on the grounds of age alone.11 However,
elderly patients who undergo pulmonary resection have a
higher incidence of morbidity and mortality than that of younger
patients because of the increased incidence of adverse medical
conditions and reduced cardiopulmonary function with aging.12
In addition, the long-term benefit of surgery in elderly patients
remains unclear because aging itself is an independent signifi-
cant predictor of poor survival.13,14
Elderly patients are generally diagnosed with early-
stage lung cancer compared with younger patients.15 Al-
though lobectomy is usually recommended for early lung
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cancer, limited surgery and other less invasive nonsurgical
alternatives could be indicated if the patient has an increased
risk of complications. Decisions regarding the treatment strat-
egy must, therefore, carefully balance the risks of postsurgi-
cal morbidity and mortality with those affecting cancer re-
currence and long-term survival.
The Japanese Joint Committee of Lung Cancer Registry
conducted retrospective studies on cancer patients in 1989,
1994, and 1999 after a 5-year follow-up.16,17 National data
were collected for 13,010 lung cancers that were resected
surgically in 1999. This study focused on patients aged 80
years and older with clinical (c)-stage I lung cancer to
elucidate predictors of long-term survival and risk factors for
postoperative complications.
PATIENTS AND METHODS
Registry
The Japanese Joint Committee of Lung Cancer Registry
performed a nationwide retrospective registry study on progno-
sis and clinicopathological profiles of patients with primary lung
cancer surgically treated in 1999 in Japan. The committee
received the registries of 13,334 patients from 387 teaching
hospitals across Japan. The questionnaire comprised 32 items
including gender, age, c-T, c-N, c-M, c-stage, preoperative
treatment, surgical procedure (pneumonectomy, lobectomy, seg-
mentectomy, or wedge resection), extent of lymph node dissec-
tion (ND0-1 or ND2: ND0, without lymph node dissection or
lymph node sampling; ND1, intrapulmonary and hilar lymph
node dissection; ND2, ND1 plus mediastinal lymph node dis-
section), curability, residual tumor, diameter of surgical tumor
specimen, histology, pathologic (p)-stage, comorbidity, preop-
erative Eastern Cooperative Oncology Group performance sta-
tus, postoperative complications, survival time, and cause of
death. For the tumor, node, metastasis staging, chest radiograph,
computed tomography (CT) of the chest, CT or ultrasound of the
upper abdomen, whole-brain CT or magnetic resonance imag-
ing, and bone scintigraphy were performed.
Patients
The study focused on patients with c-stage-I non-small
cell lung cancer (NSCLC) in octogenarians. Of the 13,334
registered patients, 602 (4.5%) were aged 80 years or older.
Clinical-stage-I patients accounted for 77.6% (467 patients)
of this age group, nine patients (1.5%) with c-stage IIA, 55
(9.1%) with IIB, 46 (7.6%) with IIIA, 12 (2.0%) with IIIB,
and six (1.0%) with c-stage IV (c-stage was not described in
seven patients). One hundred patients were excluded because
of previous treatment for lung cancer, incomplete resection,
small cell carcinoma histology, low-grade malignant histol-
ogy, or insufficient information on the factors of interest. The
remaining 367 patients were enrolled in the study and fol-
lowed for at least 5 years after surgery.
Comorbidities and Postoperative
Complications
Comorbidities and postoperative complications were
diagnosed and recorded during daily clinical practice by
laboratory, radiologic, and physiological examinations. The
questionnaires regarding comorbidity comprised 11 items:
active smoking history within 1 month before surgery, obe-
sity (body mass index, 30 kg/m2), cerebrovascular or neu-
rologic diseases, chronic obstructive pulmonary disease
(forced expiratory volume in 1 second 40%), interstitial
pneumonitis (apparent interstitial shadow detected by chest
CT), ischemic heart disease (positive stress test), renal dys-
function (serum creatinine 2.0 mg/dl), liver cirrhosis
(Child-Turcotte class B or worse), diabetes mellitus (HbA1C
8.0%), anemia (Hb 8.0 g/dl), and autoimmune disease.
The postoperative complications were as follows: wound
infection (accompanying wound failure), postoperative hem-
orrhage (500 mL/h or more), prolonged air leakage (2 weeks
or longer), chylothorax (1500 mL/d or more), bronchopleural
fistula, bronchovascular fistula, pulmonary embolism, empy-
ema, pneumonia (presenting abnormal shadow by chest ra-
diograph), respiratory failure (needed mechanical ventilation
for 3 days or longer), myocardial infarction, and cerebral
infarction.
Statistical Analysis
The survival time was measured from the date of surgery
to the date of the most recent follow-up examination. Survival
was calculated by the Kaplan-Meier method, and differences in
survival were assessed by log-rank analysis. A multivariate
analysis for prognostic factors was performed using the Cox
proportional hazard regression model. A logistic regression
model of the multivariate analysis results was used to identify
the risk factors for postoperative complications. The p values
less than 0.05 were considered statistically significant. Data are
presented as mean  standard deviation. Operative mortality
included all patients who died within the first 30 days after
surgery or during the same hospitalization.
RESULTS
Patient Characteristics
Table 1 summarizes the patient characteristics. The mean
age was 82.3 years (median, 82 years; range, 80–90 years). The
tumor histology was as follows: adenocarcinoma in 245 patients
(66.8%), squamous cell carcinoma in 100 (27.2%), large cell
carcinoma in 14 (3.8%), adenosquamous carcinoma in seven
(1.9%), and one pleomorphic or sarcomatoid carcinoma. A total
of 245 lobectomies and 122 limited resections were performed.
Limited resections included 80 wedge resections and 42 seg-
mentectomies. Concerning the c-T stage, limited resections were
performed in 94 (43.9%) of 214 patients with cT1 diseases and
28 (18.3%) of 153 patients with cT2 disease. Pneumonectomies
were not performed in this cohort. A systematic mediastinal
lymph node dissection (ND2) was performed in 127 patients
only. According to the c-T stage, ND2 was performed in 69
(32.2%) of the 214 patients with cT1 diseases and 58 (37.9%) of
the 153 patients with cT2 disease. After pathologic diagnosis of
the surgical specimens, 300 patients remained as stage I,
whereas 67 patients were diagnosed with a more advanced
disease including 44 stage II patients and 23 stage III patients.
There were 53 pathologic node-positive patients (14.4%). The
mean tumor diameter was 30.6  14.9 mm, with 113 tumors
(30.8%) smaller than 20 mm and 21 tumors (5.7%) larger than
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50 mm in diameter. Twenty-one patients (5.7%) had poor
Eastern Cooperative Oncology Group performance status, and
102 patients (27.8%) were diagnosed with some type of comor-
bidity (summarized in Table 2) before surgery. Eighteen patients
had two comorbidities and three patients had three comorbidi-
ties. The most common comorbidity was active smoking status
within 1 month of surgery. Twenty-two patients (6.0%) had
comorbid ischemic heart disease.
Analysis of Prognostic Factors
The 1-, 3-, and 5-year overall survival rates after
surgery for octogenarian patients were 89.1%, 70.6%, and
55.7%, respectively, in c-stage I NSCLC cases, 91.6%,
73.8%, and 62.0%, respectively, for c-stage IA, and 85.7%,
66.1%, and 47.2%, respectively, for c-stage IB (Figure 1A).
Because 53 patients (15.0%) were lost to follow-up, they
were censored at the date of last contact with the institution.
One hundred forty-six patients died of causes listed in Table
3. Five operative mortalities occurred within 30 days of
surgery, and 71 deaths from cancer were considered lung
cancer-related. No patients in this cohort died during the
same hospitalization later than 30 days after surgery, and 52
patients died of other causes during the 5-year follow-up
period. The calculated cause-specific 5-year survival rate
FIGURE 1. A, Postoperative overall survival curves accord-
ing to the c-stage show a significant difference between
c-stage IA and c-stage IB (p  0.0287). B, Postoperative
cause-specific survival curves according to the c-stage show
a significant difference between c-stage IA and c-stage IB
patients (p  0.0440).
TABLE 2. Details of Preoperative Comorbidity
Type of Comorbidity No. of Patients %
Smoking 40 10.9
Obesity 1 0.3
Cerebro-neural diseases 17 4.6
Chronic obstructive pulmonary disease 13 3.5
Interstitial pneumonitis 5 1.4
Ischemic heart disease 22 6.0
Renal disease 3 0.8
Liver cirrhosis 0 0.0
Diabetes mellitus 12 3.3
Anemia 0 0.0
Autoimmune diseases 1 0.3
Total 102 27.8
TABLE 1. Characteristics and Overall 5-yr Survival Rates
According to Potential Prognostic Factors of Clinical Stage I
Patients (n  367)
Variable n %
5-yr
Survival
Rate (%) p
Age, median
(range)
82 (80–90) 56.1
Gender
Male 232 63.2 47.9 0.0006
Female 135 36.8 68.8
Performance
status
0 or 1 346 94.3 56.3 0.0563
2 or 3 21 5.7 37.1
Smoking status
Current smoker 40 10.9 30.2 0.0001
Non-smoker or
Ex-smoker
327 89.1 59.2
Histology
Adenocarcinoma 245 66.8 62.3 0.0001
Squamous cell
carcinoma
100 27.2 48.8 Adenocarcinoma vs.
nonadenocarcinoma
Others 22 6.0 11.9
Clinical T
Clinical T1 214 58.3 62.4 0.0287
Clinical T2 153 41.7 47.2
Comorbidity
Yes 102 27.8 42.5 0.0007
No 265 72.2 61.0
Operative
procedure
Lobectomy 245 66.8 53.8 0.9499
Limited
resection
122 33.2 59.8
Nodal dissection
ND0-1 240 65.4 56.8 0.7616
ND2 127 34.6 53.7
Pathological stage
p-stage I 300 81.7 60.9 0.0001
p-stage II or
advanced
67 18.3 30.8
ND, lymph node dissection; ND0, without lymph node dissection or lymph node
sampling; ND1, intrapulmonary and hilar lymph node dissection; ND2, ND1 plus
mediastinal lymph node dissection.
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after surgery was 73.4%, 77.9%, and 66.9% for c-stage I,
stage IA, and stage IB patients, respectively (Figure 1B).
A univariate analysis was used to evaluate the prognos-
tic impact of nine clinicopathological factors listed in Table
1. Female gender, non-smoker or ex-smoker, adenocarci-
noma histology, c-T1, absence of comorbidity, and p-stage I
were significant prognostic factors for greater overall sur-
vival. In addition, a good performance status (0 or 1) was
marginally significant. Neither the surgical procedure (lobec-
tomy or limited surgery) nor the extent of nodal dissection
(ND0-1 or ND2) was significantly associated with survival.
Adenocarcinoma was associated with a significantly better
prognosis than squamous cell carcinoma or other carcinoma.
A multivariate analysis showed that p-stage I and absence of
comorbidity were independent significant beneficial factors
for overall survival, whereas female gender, adenocarcinoma
histology, and better performance status were marginally
significant (Table 4).
Risk Factors for Postoperative Complications
A total of 31 patients (8.4%) presented with postoper-
ative complications (Table 5). Two complications occurred in
five patients. The most common complications in order of
frequency were pneumonia followed by prolonged air leak-
age (2 weeks). A multivariate analysis identified mediasti-
nal lymph node dissection (ND2) and comorbidity as signif-
icant factors associated with increased risk of postoperative
complications (Table 6). Interestingly, performance status,
which is a well-recognized risk factor, was not significantly
associated with postoperative complications. The reason for
this could be that there was a very few percentage of the
patients with a poor performance status.
Five patients (1.4%) died within 30 days of surgery,
and each had undergone a lobectomy. Table 7 summarizes
the clinical courses of these patients: four had (a) comorbid
disease(s) with pneumonia in three patients, cerebral infarc-
tion in two, and myocardial infarction and pulmonary embo-
lism in one patient. Thus, the operative mortality rate was
2.0% (five of 245) after lobectomy and zero after limited
resection.
DISCUSSION
Surgery offers the highest probability of cure in all
patients with early-stage lung cancer. However, surgeons
often hesitate to recommend surgery for elderly patients
because of the higher perioperative risks and the uncertainty
of long-term benefit. As Japanese citizens who are 80 years
old are expected to live for an additional 8.2 years for men
and 11.1 years for women,2 a radical treatment should be
considered. More information regarding the short-term and
long-term postoperative outcomes would help surgeons to
select a subgroup of elderly patients suitable for a pulmonary
resection. This study analyzed 367 patients aged from 80 to
90 years with c-stage I NSCLC. These patients accounted for
2.8% of all lung cancers in the registry.
The long-term results in this study were satisfactory.
The 5-year survival rate was superior to those reported
recently in a large cohort of octogenarians: 48% for p-stage
IA and 39% for p-stage IB,10 although single institutional
studies with smaller numbers of patients have presented
TABLE 3. Summary of Causes of Death During 5-yr
Follow-up
Cause of Death
No. of
Patients %
Percentage of
all Deaths
Surgical mortality 5 1.4 3.4
Lung cancer-related death 71 19.3 48.6
Other cancer-related death 8 2.2 5.5
Died of nonmalignant diseases 44 12.0 30.1
Unknown 18 4.9 12.3
Total 146 39.8 100
TABLE 4. Multivariate Analysis of Survival in Clinical Stage I Cases: Cox Proportional Hazard Model
Variable Reference HR 95% CI p
Gender (female) Male 0.691 0.466–1.027 0.067
Performance status (2 or 3) 0 or 1 1.829 0.977–3.423 0.059
Histology (non-adenocarcinoma) Adenocarcinoma 1.390 0.966–2.000 0.076
Clinical T (cT2) cT1 1.220 0.858–1.733 0.268
Operative procedure (limited resection) Lobectomy 1.126 0.756–1.679 0.559
Nodal dissection (ND2) ND0-1 1.093 0.747–1.598 0.648
Pathological stage (p-stage II or advanced) p-stage I 2.149 1.471–3.141 0.0001
Comorbidity (No) Yes 0.678 0.475–0.966 0.032
HR, hazard ratio; CI, confidence interval; ND2, ND1 plus mediastinal lymph node dissection.
TABLE 5. Details of Major Postoperative Complications
Type of Complication No. of Patients %
Pneumonia 17 4.6
Prolonged air leakage 7 1.9
Cerebral infarction 3 0.8
Empyema 2 0.5
Wound infection 1 0.3
Bronchopleural fistula 1 0.3
Pulmonary embolism 1 0.3
Respiratory failure 1 0.3
Myocardial infarction 1 0.3
Other 2 0.5
Total 31 8.4
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better long-term survivals.7,8,18 There are several possible
reasons for these differences. First, this study was limited to
preoperative stage I patients. Second, the number of patients
with a large tumor (50 mm in diameter) was less than that
in the report citing lower survival rates.10 Third, as expected
from the country with the world’s highest life expectancy
(78.5 years for men and 85.5 years for women2), Japanese
octogenarians may have better physiological and medical
conditions in comparison with the elderly in other countries.
A multivariate analysis identified p-stage and comor-
bidity status as significant factors influencing long-term sur-
vival. Although p-stage is a well-known prognostic factor, the
role of comorbidity in prognosis is less clear.19,20 Any dis-
cussion of prognostic factors should consider that lung can-
cer-related deaths accounted for only 76 (52.1%) of the 146
deaths recorded in this study. Thus, comorbidity might influ-
ence the risk for death from causes other than lung cancer in
elderly patients, as previously studied by Charlson et al.21 Of
note, the 5-year lung cancer-specific survival rates in this
study (77.9% for c-stage IA and 66.9% for c-stage IB) were
almost equivalent to those for the general population in
Japan.14,17 Surgeons should therefore consider comorbid dis-
eases and preoperative staging in selecting those elderly
patients most likely to achieve long-term benefit from pul-
monary resection.
Postoperative complications were observed in 8.4% of the
patients in this study. Comorbidity and mediastinal lymph node
dissection (ND2) were identified as risk factors for increased
postoperative complications by the multivariate analysis. Previ-
ous studies in elderly patients also proposed mediastinal lymph
node dissection as a risk factor for postoperative complica-
tions.22,23 From the surgical point of view, recurrent nerve
exposure, devascularization of the bronchial wall, and increased
surgical exudates or bleeding due to mediastinal lymph node
dissection are thought to be associated with several possible
complications. However, this procedure is necessary for a com-
plete resection in the patients with subclinical nodal diseases,
accounting for 14.4% of the cohort in this study. Recently,
advanced technologies such as 2-fluoro-2-deoxyglucose-
positron emission tomography and endobronchial ultrasound-
guided transbronchial needle aspiration have been available to
evaluate hilar and mediastinal lymph nodes. These modalities
could help in selecting the patients who can be cured without
mediastinal lymph node dissection. In this regard, a more accu-
rate preoperative staging may facilitate to decrease the postop-
erative complications.
The recommended surgical treatment for c-stage I pa-
tients is lobectomy and mediastinal lymph node evaluation.5
However, a limited resection and a lesser extent of lymph
node dissection (ND0-1) were commonly performed in this
study (limited resection in 33.2% and ND0-1 in 65.4% of
patients) in comparison with the general population (limited
resection in 4.7% and ND0-1 in 11.9%14). Although the
reasons for selection of these procedures by the surgeons
were not recorded in the registry, it is assumed that the
surgeons intended to reduce the perioperative risks. Interest-
ingly, the present study found no significant difference in the
long-term survival of elderly patients between those who
TABLE 6. Multivariate Analysis of Postoperative Complications in Clinical Stage I Cases: Logistic Regression Model
Variable Reference OR 95% CI p
Factors in the final model
Nodal dissection (ND2) ND0-1 2.292 1.056–4.974 0.036
Comorbidity (Yes) No 5.347 2.451–11.666 0.0001
Factors not in the final model
Gender (female) Male 0.73 0.275–1.939 0.528
Performance status (2 or 3) 0 or 1 2.877 0.103–2.877 0.103
Histology (non-adenocarcinoma) Adenocarcinoma 1.011 0.431–2.375 0.979
Operative procedure (limited resection) Lobectomy 0.913 0.337–2.471 0.857
Clinical T (cT2) cT1 1.455 0.626–3.380 0.384
OR, odds ratio; CI, confidence interval; ND2, ND1 plus mediastinal lymph node dissection.
TABLE 7. Clinical Background of Operative Mortalities
Case Age Gender PS c-Stage Comorbidity Surgery
Nodal
Dissection p-Stage
Postoperative
Complications
1 82 Male 1 IA Smoking, autoimmune disease Lobectomy ND2 IA Cerebral infarction
2 81 Female 2 IA Cerebro-neural disease Lobectomy ND1 IB Myocardial infarction,
pneumonia
3 80 Male 2 IB Diabetes mellitus Lobectomy ND1 IB Cerebral infarction,
pneumonia
4 80 Male 0 IB None Lobectomy ND0 IB Pneumonia
5 80 Male 0 IB Smoking, Interstitial pneumonitis Lobectomy ND2 IB Pulmonary embolism
ND, lymph node dissection; ND0, without lymph node dissection or lymph node sampling; ND1, intrapulmonary and hilar lymph node dissection; ND2, ND1 plus mediastinal
lymph node dissection; PS, Performance status.
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underwent limited resection and lobectomy. This conflicts
with a previous study from the Japan Lung Cancer Registry
suggesting that lobectomy or pneumonectomy was a predic-
tor of a good outcome for patients with stage I cancer in the
general population.14 According to data from The National
Cancer Registry in the United States,24 lobectomies confer a
significant survival benefit over limited resections, except in
patients 71 years of age. Taken together, these findings
implicate limited resection as an important alternative treat-
ment for elderly patients with early-stage lung cancer despite
lobectomy still being the ideal surgical option when the
patient can tolerate the procedure. Consequently, minimizing
surgical intervention in terms of both pulmonary resection
and lymph node dissection should be considered to treat
elderly patients with early-stage NSCLC as long as complete
resection could be performed.
The operative mortality rate of 1.4% in this study was
lower than those cited in recent studies with large sample
sizes that described hospital mortality/30-day hospital mor-
tality ranging from 2.2 to 8.8%.8,20 The rate in this study is
also comparable with the mortality rate of lung cancer resec-
tion in the total population.17,25 Possible reasons for this
low-mortality rate include the lower rate of patients with
comorbid diseases and the higher proportion of patients
undergoing less invasive surgery in this study.
Nonsurgical local therapies are currently used in the
treatment of stage I lung cancer.26–29 In most cases, these
therapies are indicated for high-risk patients unfit for surgery.
Furthermore, recent technological advances have greatly im-
proved the long-term results of these modalities with low
treatment-related mortality. The benefits and the morbidity of
surgery need to be carefully weighed against these less
invasive approaches, especially in elderly patients. At
present, there is little information available on comparison of
these modalities with surgery with respect to overall survival
rates and disease recurrence.30 A clinical trial comparing the
short- and long-term results of these different modalities would
reliably help future surgical decision making with regard to
treatment of local lung cancer in the elderly. Until such studies
are performed, the results obtained in the present surgical series
may constitute a basis on which to compare results.
The strengths of this study include the large sample
size, the nationwide multi-institutional nature of the data,
homogenous oncological status, minimum patients lost to
follow-up, and the availability of complete pathologic find-
ings. Limitations were that the study was retrospective, and
that comorbidity status and postoperative complications were
not described in detail. Several objective measurements can
be used to evaluate and describe comorbidity and complica-
tions, as used in various previous studies.19,31–33 Such scoring
systems enable comparison of the results among studies
involving different patient backgrounds and treatment modal-
ities. Activity of daily living and quality of life after surgery,
not evaluated in this study, are also very important concerns
for elderly patients and their family to consider when decid-
ing to undergo surgery. In addition, the smoking history was
not taken. If a patient quit smoking 1 month before surgery,
the patient was categorized into a group of nonsmokers. This
was the reason why the percentage of current smokers was
low (10.7%).
In summary, the long-term results of c-stage I NSCLC
in octogenarians were satisfactory, with a 5-year survival rate
of 55.7% for c-stage I, 62.0% for c-stage IA, and 47.2% for
c-stage IB. Pathologic stage II or higher cancer and the
presence of comorbidity were significantly independent fac-
tors predicting short survival, whereas comorbidity and me-
diastinal lymph node dissection (ND2) were independent risk
factors for postoperative complications.
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